301033 Medprin Regenerative Medical Technologies
- 46.72
- 0.000.00%
Medprin Regenerative Medical Technologies News
Maipu Medical (301033): Profits exceed expectations, rapid release of new products
Maipu Medical (301033): Rapid year-on-year growth in performance to create high-end neurosurgeons overseas
Maipu Medical (301033): Domestic product penetration rate rapidly increased, overseas brand influence continued to expand, and the company entered a period of rapid development
Maipu Medical (301033): A leader in the field of neurosurgical implantation medical devices
Maipu Medical (301033) 2024 Interim Report Review: High Performance Growth, Rapid Release of New Products
Maipu Medical (301033): Procurement drives rapid sales growth in sales volume, innovative product sales
Maipu Medical (301033) Company Review: Accelerated Collection Improves Penetration Rate 24H1 Endogenous Growth Strong
Maipu Medical (301033): High-value consumables innovation platform company accelerates import substitution of Shenwai consumables
Maipu Medical (301033): Collection execution drives volume acceleration, outstanding performance
Maipu Medical (301033) Commentary on important matters: The release of a 24-year restricted stock incentive plan highlights confidence in long-term development
Maipu Medical (301033): The company released a new version of the equity incentive draft, and the performance assessment goals are more positive
Maipu Medicine (301033): Neurosurgery department collaborates to go overseas to open up space for growth
Maipu Medicine (301033): Driven by innovation to lead the field of new materials in domestic neurosurgery
Maipu Medical (301033) In-depth Research Report: Shenwai Platform Company Sets Sail
Maipu Medicine (301033): The collection pressure period has passed, and both domestic and overseas harvests have passed
Guoyuan Securities released a research report on April 25 stating that it gave Maipu Medical (301033.SZ) a purchase rating. The main reasons for the rating include: 1) rapid penetration of the craniomaxillofacial product group, accelerated release of new
Commentary on Maipu Medical (301033) 2023 Report and 2024 First Quarter Report: Collection is expected to accelerate product penetration into new products and shine
Maipu Medical (301033): The company's new product launch is imminent, and the second growth curve is gradually becoming large-scale
Maipu Medical (301033): The impact of the collection policy is gradually showing that fresh products are being released, and the company is expected to usher in a period of rapid growth
Maipu Medical (301033) First Coverage Report: A Leader in Progressively Platformizing Synthetic Neurosurgical Material Implantation Devices
No Data
